type III hypersensitivity disease

Summary

type III hypersensitivity disease (MONDO:0007004) is a disease. A subtype of hypersensitivity reaction disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	type III hypersensitivity disease
Mondo ID	MONDO:0007004
EFO	EFO:1001222
MeSH	D007105
DOID	DOID:1557
NCIT	C114346
UMLS	C0020951
MedGen	7021
MedDRA	10045265
Is cancer (heuristic)	no

Also known as: disorder of type III hypersensitivity · type 3 hypersensitivity reaction · type III hypersensitivity · type III hypersensitivity reaction

Disease family

This is a subtype of hypersensitivity reaction disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › hypersensitivity reaction disease › type III hypersensitivity disease

Related subtypes (9): type IV hypersensitivity disease, allergic disease, hypersensitivity vasculitis, IgE responsiveness, atopic, immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome, progestogen hypersensitivity, type II hypersensitivity reaction disease, pseudoallergy, anaphylaxis

Subtypes (2): arthus reaction, serum sickness

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

8 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Betamethasone Acetate	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Epinephrine	Approved (phase 4)
Hydrocortisone	Approved (phase 4)
Methylprednisolone Acetate	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)
Triamcinolone Acetonide	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.